Understanding liver disease linked to alcohol and metabolic syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify metabolic and immune factors, along with medical imaging data, that contribute to the development of Hepatocellular Carcinoma (HCC) in patients with alcohol-related liver disease and Non-Alcoholic Steatohepatitis (NASH). It will include both cirrhotic and non-cirrhotic patients to uncover early molecular mechanisms leading to HCC. Participants will undergo a variety of assessments including dietary questionnaires, physical activity evaluations, and liver biopsies, with the collection of biological samples for future research. The study is expected to span over 10 years, with patient participation lasting from one day to two months.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Criteria common to all patients:

  1. Affiliation to French social security.
  2. Male or female ≥ 18 years of age
  3. Patients able to receive and understand information about the research and to give written informed consent duly signed by the patient and the investigator (at the latest on the day of inclusion and before any examination necessary for the research).
* Patients in the NAFLD group with HCC:

  1. Alcohol consumption ≤ 30 g pure alcohol/d (or 210 g pure alcohol/week) for men and ≤ 20 g pure alcohol/d (140 g pure alcohol/week) for women.
  2. Decision, less than 3 months old, of liver biopsy of the suspected HCC nodule and non-tumour liver tissue performed as a clinical routine.
  3. No systemic treatment for HCC within 6 months prior to inclusion.
* Patients in the NAFLD group without HCC:

  1. Alcohol consumption ≤ 30 g pure alcohol/d (or 210 g pure alcohol/week) for men and ≤ 20 g pure alcohol/d (140 g pure alcohol/week) for women.
  2. Decision of less than 3 months of a liver biopsy performed as a clinical routine. Biopsy will be motivated by liver function disturbance(s) and/or ultrasound steatosis given the lack of validated non-invasive tests or the lack of accuracy (grey areas) of available non-invasive tests for the diagnosis of necro-inflammation and/or fibrosis in some of these patients.
* Patients in the alcohol-related liver disease group with HCC:

  1. Alcohol consumption \> 30 g pure alcohol/d (or 210 g pure alcohol/week) for men and \> 20 g pure alcohol/d (140 g pure alcohol/week) or binge drinking
  2. Decision within 3 months of liver biopsy of suspected HCC nodule and non-tumour liver tissue performed as part of clinical routine
  3. No systemic treatment for HCC within 6 months prior to inclusion.
* Patients in the alcohol-related liver disease group without HCC:

  1. Alcohol consumption \> 30 g pure alcohol/d (or 210 g pure alcohol/week) for men and \> 20 g pure alcohol/d (140 g pure alcohol/week) or binge drinking
  2. Decision of less than 3 months for a liver biopsy to be performed as a clinical routine. Biopsy will be motivated by liver balance disturbance(s) and/or ultrasound steatosis given the lack of validated non-invasive tests or the lack of accuracy (grey areas) of available non-invasive tests for the diagnosis of necro-inflammation and/or fibrosis in some of these patients.

Exclusion Criteria:

1. Positive HIV serology
2. Patients with detectable hepatitis C viral load
3. Presence of Hbs antigen
4. History of autoimmune hepatitis type 1 or 2, primary biliary cholangitis, primary sclerosing cholangitis, Wilson's disease, genetic haemochromatosis homozygous, alpha1 anti-trypsin deficiency
5. Long-term use of methotrexate, corticosteroids, anti-Tumor Necrosis Factor cyclosporine, tacrolimus
6. History of solid organ transplantation or bone marrow transplantation
7. Cancerous disease in the process of being treated, except for skin cancer (excluding melanoma)
8. Patients under legal protection or unable to express their consent,
9. Pregnant or breastfeeding women

Where it's running

• Batiment Archimed 151, route de Saint Antoine de Ginestière
  Nice, France Recruiting

Study contacts

• Study coordinator: Rodolphe Anty, MD, PhD
• Email: anty.r@chu-nice.fr
• Phone: 0033492035943

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bile acid and gut microbiota changes in people with hepatitis D starting bulevirtide

  This project will see if starting bulevirtide changes bile acids and gut bacteria in adults with chronic hepatitis D who are already on hepatitis B therapy.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07429864

• Blood markers to detect liver scarring in fatty liver disease

  This will test whether blood markers can detect liver scarring in adults with NAFLD or NASH who are having or recently had a liver biopsy.

  Recruiting at 2 sites Roche Diagnostics GmbH · Copenhagen and 1 other locations · NCT06819917

• Treatment for advanced liver cancer with specific cirrhosis

  This study is testing a new combination treatment for advanced liver cancer in patients with specific cirrhosis to see if it can help them better than current options, especially focusing on those from underserved communities.

  Recruiting Phase 2 The University of Texas Health Science Center at San Antonio · San Antonio, Texas · NCT06526104

• Endoscopic sleeve gastroplasty for people with obesity and MASH

  This study will test whether endoscopic sleeve gastroplasty plus lifestyle changes helps adults with obesity and MASH lose weight and improve liver health compared with lifestyle changes alone.

  Recruiting at 2 sites Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT06138821

• Improving early diagnosis of liver cancer in high-risk patients in China

  This study is testing if regular check-ups for liver cancer can help catch the disease earlier in people at high risk due to conditions like chronic hepatitis or cirrhosis in China.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT05870969

• Using endoscopic ultrasound to assess liver stiffness in patients with fatty liver disease

  This study is testing if a special ultrasound can help find liver damage in people with fatty liver disease who are overweight, comparing it to other methods to see which works best.

  Recruiting at 2 sites Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT05728697

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.